Parthenon LLC Sells 185 Shares of Zoetis Inc. (NYSE:ZTS)

Parthenon LLC lessened its holdings in Zoetis Inc. (NYSE:ZTS) by 1.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 9,558 shares of the company’s stock after selling 185 shares during the period. Parthenon LLC’s holdings in Zoetis were worth $1,557,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of ZTS. Cherry Creek Investment Advisors Inc. lifted its stake in Zoetis by 2.0% in the third quarter. Cherry Creek Investment Advisors Inc. now owns 3,021 shares of the company’s stock worth $590,000 after purchasing an additional 58 shares during the last quarter. Hancock Whitney Corp raised its holdings in shares of Zoetis by 0.3% in the third quarter. Hancock Whitney Corp now owns 18,569 shares of the company’s stock worth $3,628,000 after buying an additional 61 shares during the period. Strategy Asset Managers LLC raised its holdings in shares of Zoetis by 3.5% in the third quarter. Strategy Asset Managers LLC now owns 1,822 shares of the company’s stock worth $356,000 after buying an additional 62 shares during the period. VeraBank N.A. lifted its stake in shares of Zoetis by 4.1% during the 4th quarter. VeraBank N.A. now owns 1,562 shares of the company’s stock worth $254,000 after acquiring an additional 62 shares during the last quarter. Finally, Procyon Advisors LLC boosted its holdings in Zoetis by 1.4% during the 4th quarter. Procyon Advisors LLC now owns 4,712 shares of the company’s stock valued at $768,000 after acquiring an additional 63 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Insider Buying and Selling at Zoetis

In other news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the sale, the executive vice president now owns 16,107 shares in the company, valued at approximately $2,757,196.26. This represents a 1.98 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.16% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of analysts have weighed in on ZTS shares. Piper Sandler reduced their target price on Zoetis from $210.00 to $200.00 and set an “overweight” rating on the stock in a research note on Monday, February 10th. Barclays raised their price target on shares of Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research note on Friday, February 14th. Leerink Partners assumed coverage on shares of Zoetis in a research report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price objective for the company. Morgan Stanley dropped their target price on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research note on Friday, February 14th. Finally, UBS Group assumed coverage on shares of Zoetis in a research note on Monday, December 9th. They set a “neutral” rating and a $196.00 price target for the company. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $214.90.

Zoetis Trading Up 0.3 %

Shares of NYSE:ZTS opened at $156.92 on Thursday. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. The company has a market capitalization of $70.27 billion, a PE ratio of 28.69, a P/E/G ratio of 2.77 and a beta of 0.90. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $200.53. The business’s fifty day simple moving average is $167.29 and its 200-day simple moving average is $178.29.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.37 by $0.03. The company had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. As a group, equities research analysts predict that Zoetis Inc. will post 6.06 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be given a dividend of $0.50 per share. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a yield of 1.27%. Zoetis’s payout ratio is 36.56%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.